ENSIGN:ENdothelial JAK-STAT SIGNalling in myeloproliferative neoplasms

• Research type

  Research Study

• Full title

  ENSIGN: Does ENdothelial JAK-STAT SIGNalling drive vascular inflammation and dysfunctional haemostasis in patients with myeloproliferative neoplasms?

• IRAS ID

  263665

• Contact name

  David Allsup

• Contact email

  david.allsup@hey.nhs.uk

• Sponsor organisation

  University of Hull

• Duration of Study in the UK

  10 years, 0 months, 0 days

• Research summary

  Myeloproliferative neoplasms (MPNs) are a group of three related blood cancers for which there is currently no cure. A common cause of MPNs is a change in a protein called Janus kinase 2 (termed VF-JAK2) which permanently turns it on. One effect of this is uncontrolled blood clotting or bleeding that reduces quality of life and life expectancy. Research has shown the presence of VF-JAK2 in cells lining blood vessel walls (endothelial cells) mimics the haemostatic complications seen in MPNs. Therefore, treatments that inhibit VF-JAK2 in endothelial cells could improve quality of life for people with MPNs.
  Therefore we want to test if approaches that can effectively and safely inhibit VF-JAK2 in endothelial cells can reduce haemostatic complications in MPN patients.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  20/PR/0039

• Date of REC Opinion

  19 Oct 2020

• REC opinion

  Further Information Favourable Opinion